Michael Barbella, Managing Editor06.27.22
Inogen Inc. has appointed Agnes Lee as senior vice president of Investor Relations and Strategic Planning.
“I am excited to welcome Agnes to the Inogen team as we continue to strengthen our strategic planning capabilities, further execute against our growth initiatives and communicate our strategy internally and externally, all with the overarching goal of transforming Inogen and driving shareholder value," President and CEO Nabil Shabshab said. "Agnes brings extensive medical technology and life sciences experience and has an excellent track record in effective engagement with shareholders and analysts.”
Lee joins Inogen from Butterfly Network, where she served as vice president of Investor Relations. While at Butterfly, she created an investor relations program to promote the company to analysts and investors and collaboratively led investor marketing to reflect an evolution of the company’s vision and strategy. Prior to Butterfly, Lee led proactive investor relations programs at Fluidigm and ResMed Inc., playing pivotal roles in communicating changes in strategy, and global investor marketing. She started her investor relations career at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. Before that role, Lee spent almost a decade serving in increasing finance leadership roles at Life Technologies, Applied Biosystems, and Celera Diagnostics. She also worked in investment banking earlier in her career.
Lee earned an MBA in finance and marketing from the Kellogg School of Management at Northwestern University and a bachelor of arts degree in economics and international affairs from Indiana University Bloomington.
“I am thrilled to join Inogen at such an exciting time in Inogen’s journey. I have been impressed by the work that Nabil and the rest of the management team have done to transform Inogen. There is a tremendous opportunity ahead for the company and I look forward to working with the team to evolve our long-term strategy and communicate that story to investors,” Lee said.
Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. The company primarily develops, manufactures, and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
“I am excited to welcome Agnes to the Inogen team as we continue to strengthen our strategic planning capabilities, further execute against our growth initiatives and communicate our strategy internally and externally, all with the overarching goal of transforming Inogen and driving shareholder value," President and CEO Nabil Shabshab said. "Agnes brings extensive medical technology and life sciences experience and has an excellent track record in effective engagement with shareholders and analysts.”
Lee joins Inogen from Butterfly Network, where she served as vice president of Investor Relations. While at Butterfly, she created an investor relations program to promote the company to analysts and investors and collaboratively led investor marketing to reflect an evolution of the company’s vision and strategy. Prior to Butterfly, Lee led proactive investor relations programs at Fluidigm and ResMed Inc., playing pivotal roles in communicating changes in strategy, and global investor marketing. She started her investor relations career at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. Before that role, Lee spent almost a decade serving in increasing finance leadership roles at Life Technologies, Applied Biosystems, and Celera Diagnostics. She also worked in investment banking earlier in her career.
Lee earned an MBA in finance and marketing from the Kellogg School of Management at Northwestern University and a bachelor of arts degree in economics and international affairs from Indiana University Bloomington.
“I am thrilled to join Inogen at such an exciting time in Inogen’s journey. I have been impressed by the work that Nabil and the rest of the management team have done to transform Inogen. There is a tremendous opportunity ahead for the company and I look forward to working with the team to evolve our long-term strategy and communicate that story to investors,” Lee said.
Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. The company primarily develops, manufactures, and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.